Clinical Trial Update: Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating hepatectomy combined with camrelizumab and apatinib in CNLC stage IIIb hepatocellular carcinoma is ongoing with unknown status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN